Symptom Management Implementation of Patient Reported Outcomes in Oncology

  • STATUS
    Recruiting
  • End date
    Sep 30, 2023
  • participants needed
    18000
  • sponsor
    Dana-Farber Cancer Institute
Updated on 15 November 2021
cancer
symptom control
cancer care
gastrointestinal cancer
gastrointestinal surgery
gynecologic surgery

Summary

Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM

Description

A multi-disciplinary team of investigators from 6 health systems have formed the Symptom Management IMplementation of Patient Reported Outcomes in Oncology (SIMPRO) Research Center. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM. eSyM is the name of the platform the team will refine, integrate, implement and evaluate. eSyM addresses each of the 4 evidence gaps by:

  • Implementing eSyM in cancer centers in small, rural or community-based systems.
  • Integrating eSyM into the EHR of the predominant vendor used nationwide.
  • Leveraging evidence-based tools, patient engagement, and population management.
  • Executing this work using the Consolidated Framework for Implementation Research across all phases to maximize the chances that eSyM and similar systems achieve their intended goals and decrease the morbidity of cancer treatment at a population level.

This project contains 4 activities:

  1. Obtain stakeholder feedback
  2. Build and deploy eSyM
  3. Pilot test eSyM
  4. Pragmatic stepped-wedge cluster randomized trial

Details
Condition Gastrointestinal Neoplasm, GASTROINTESTINAL DISORDER, Neoplasm of unspecified nature of digestive system, Gastrointestinal Diseases and Disorders, Other Cancer, Gynecologic Cancer, Thoracic Cancer, Digestive System Neoplasms, gastrointestinal cancer, other malignancy, cancer other, gastrointestinal cancers
Treatment eSyM App Usage, SASS Questionnaire
Clinical Study IdentifierNCT03850912
SponsorDana-Farber Cancer Institute
Last Modified on15 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Activity 1 Population
Age 18 years
The potential stakeholders are: patient advisory council members, health system leaders, clinicians, clinic support staff/administration, IT/Informatics staff
Activity 3 Population
Age 18 years
Priority population will be patients who meet one of the following
Suspected thoracic cancer [lung or bronchus] AND is inpatient following thoracic surgery
Suspected gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND is inpatient following gastrointestinal surgery
Suspected gynecologic cancer [ovary, uterus, or cervix] AND is inpatient following gynecologic surgery
Diagnosis of thoracic cancer [lung or bronchus] AND scheduled to start a new treatment plan for thoracic cancer
Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND scheduled to start a new treatment plan for gastrointestinal cancer
Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND scheduled to start a new treatment plan for gynecologic cancer
Total population allowed to use eSyM
Any patient at any participating site
Activity 4 Population
Age 18 years
Priority population will be patients who meet one of the following
Suspected thoracic cancer [lung or bronchus] AND is inpatient following thoracic surgery
Suspected gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND is inpatient following gastrointestinal surgery
Suspected gynecologic cancer [ovary, uterus, or cervix] AND is inpatient following gynecologic surgery
Diagnosis of thoracic cancer [lung or bronchus] AND scheduled to start a new treatment plan for thoracic cancer
Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND scheduled to start a new treatment plan for gastrointestinal cancer
Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND scheduled to start a new treatment plan for gynecologic cancer
Total population allowed to use eSyM
Any patient at any participating site
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note